The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven Aspergillosis
Abstract
The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53% of patients and exceeded 2.5 mg/dL in 29%; 14.5% underwent dialysis; and 60% died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P<.001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P<. 001), and autologous BMT patients (HR, 5.06; P=.024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3. 089; P<.001), duration of amphotericin B use (HR, 1.03 per day; P=. 015), and use of nephrotoxic agents (HR, 1.96; P=.017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P=.002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Self-citationPrentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Nephrotoxicity of Amphotericin B
Butler, W. T., BENNETT, J. E., ALLING, D. W., WERTLAKE, P. T., UTZ, J. P., & HILL, G. J. (1964) · Annals of Internal Medicine · doi:10.7326/0003-4819-61-2-175 · Cited by 326
Anaissie, E. J., Vartivarian, S. E., Abi-Said, D., Uzun, O., Pinczowski, H., Kontoyiannis, D. P., Khoury, P., Papadakis, K., Gardner, A., Raad, I. I., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)80072-6 · Cited by 188
Self-citationAmphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166
Self-citationKENNEDY, M. S., DEEG, H. J., SIEGEL, M., CROWLEY, J. J., STORB, R., & THOMAS, E. D. (1983) · Transplantation · doi:10.1097/00007890-198303000-00005 · Cited by 159
MILLER, R. P., & BATES, J. H. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-6-1089 · Cited by 145
Ng, T., & Denning, D. W. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100129015 · Cited by 134
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationPractice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Next-generation biomarkers for detecting kidney toxicity
Bonventre, J. V., Vaidya, V. S., Schmouder, R., Feig, P., & Dieterle, F. (2010) · Nature Biotechnology · doi:10.1038/nbt0510-436 · Cited by 538
Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury
Waikar, S. S., Liu, K. D., & Chertow, G. M. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05191107 · Cited by 533
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Self-citationInjectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458
Self-citationAmphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Deray, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.37 · Cited by 400
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., Verschakelen, J., & Boogaerts, M. (2002) · The Journal of Infectious Diseases · doi:10.1086/343804 · Cited by 343
Invasive Aspergillosis in 2002: An Update
Kontoyiannis, D., & Bodey, G. (2002) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0699-z · Cited by 326
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Overview of the lipid formulations of amphotericin B
Dupont, B. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.31 · Cited by 260
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Garnacho-Montero, J., Amaya-Villar, R., Ortiz-Leyba, C., León, C., Álvarez-Lerma, F., Nolla-Salas, J., Iruretagoyena, J. R., & Barcenilla, F. (2005) · Critical Care · doi:10.1186/cc3488 · Cited by 252
Potential Use of Phenolic Acids as Anti-Candida Agents: A Review
Teodoro, G. R., Ellepola, K., Seneviratne, C. J., & Koga-Ito, C. Y. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01420 · Cited by 204
Anidulafungin: A new echinocandin with a novel profile
Vazquez, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.010 · Cited by 78
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis
Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.01.014 · Cited by 43
Metadata
- Authors
- Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., Bowden, R., Anaissie, E., Hiemenz, J., & Lister, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-12
- Volume
- 29
- Issue
- 6
- Pages
- 1402-1407
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168688421
- Cited by
- 368
- References
- 14
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.